SCHEMBL1744270

SCHEMBL1744270

O=Cc1ccc(-c2ccc(N3CCN(CC4CC4)CC3)nn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.42
RAB9A P51151 5/20 0.42
PARP1 P09874 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP17A1 P05093 1/20 0.38
CYP21A2 P08686 1/20 0.38
CYP11B1 P15538 1/20 0.38
MAPT P10636 4/20 0.37
TP53 P04637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SCD O00767 1/20 0.36
CASP1 P29466 1/20 0.36
CASP4 P49662 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3970574 0.84 MAPT (0.47) NPC1RAB9APARP1MEN1KMT2A
SCHEMBL1742433 0.82 SCD (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1743100 0.81 RET (0.43) PARP1CYP17A1CYP21A2CYP11B1CASP1
SCHEMBL1744279 0.81 NPC1 (0.41) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL3970310 0.81 LMNA (0.45) NPC1RAB9APARP1MAPTTP53
SCHEMBL3967589 0.81 SCD (0.51) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1742263 0.80 NPC1 (0.38) NPC1RAB9APARP1MEN1KMT2A
SCHEMBL1743448 0.79 HRH3 (0.46) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1743176 0.79 HRH3 (0.46) NPC1RAB9ACASP1CASP4CASP5
SCHEMBL1742261 0.78 NPC1 (0.47) NPC1RAB9APARP1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
CN-103110635-A Histamine H3 receptor antagonist NOVO NORDISK AS 2013-05-22 CN disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
CN-101218206-A Histamine H3 receptor antagonists NOVO NORDISK AS (DK) 2008-07-09 CN disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 NPC1 2646/4885RAB9A 4607/4885PARP1 3972/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 NPC1 2646/4885RAB9A 4607/4885PARP1 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.